JOURNAL ON COMMUNICATIONS

ISSN:1000-436X

Scopus®

REGISTERED

www.jocs.review

Nanostructured Lipid Carriers (NLCs): Versatile Platforms for Advanced Drug Delivery and Biomedical Applications

Dr. Swami Avinash B.[a*], Ms. Patil Pooja Y.[b], Ms. Agwane S. G.[c], Dr. Dhole Shital M.[d]
[a]Associate professor, Mangaldeep Institute of Pharmacy, Nipani, Chh. Sambhajinagar
Chh. Sambhajinagar - 431001, Maharashtra, India
[b]PhD scholar, Datta Meghe Institute of Higher Education and Research, Sawangi (Meghe), Wardha
Wardha - 442107, Maharashtra, India
[c]Assistant professor, NBS Institute of Pharmacy, Ausa - 413520, Latur, Maharashtra, India
[d]Associate professor, Saraswati Institute of Pharmacy, Pangri, Nanded
Pangri - 403606, Maharashtra, India

Abstract: Nanotechnology has revolutionized drug delivery, with Nanostructured Lipid Carriers (NLCs) emerging as versatile platforms overcoming traditional limitations. This review explores the nanostructure, composition, preparation methods, and diverse applications of NLCs. NLCs, evolving from Solid Lipid Nanoparticles (SLNs), incorporate both solid and liquid lipids, enhancing drug loading, stability, and controlled release. Various preparation methods like high-pressure homogenization, solvent evaporation, hot/cold homogenization, and microemulsion techniques offer tailored approaches for NLC synthesis. NLCs find extensive applications including oral, topical, transdermal, and parenteral drug delivery, cancer therapy, ophthalmic treatments, imaging, cosmeceuticals, gene delivery, and veterinary medicine. Despite challenges, NLCs demonstrate immense potential in advancing pharmaceutical and biomedical fields.

Keywords: Nanotechnology, Nanostructured lipid carriers (NLCs), Solid lipid nanoparticles (SLNs), Targeted drug delivery, Lipid-based nanoparticles, Biocompatibility,

***Corresponding author**

Dr. Swami Avinash B.
M. Pharm, Ph.D.
Associate Professor,
Department of Pharmaceutics,
Mangaldeep Institute of Pharmacy, Nipani, Chh. Sambhajinagar
Chh. Sambhajinagar - 431001, Maharashtra, India
Mobile: +91 8855878145 / 7972094559

Introduction:

Nanotechnology has revolutionized the field of drug delivery by offering novel platforms capable of overcoming traditional limitations associated with pharmaceutical formulations. Among these, Nanostructured Lipid Carriers (NLCs) stand out as versatile colloidal delivery systems with immense potential in enhancing the therapeutic efficacy of various drugs.

Nanostructured lipid carriers (NLCs) are colloidal drug delivery systems that have gained significant attention in pharmaceutical research due to their unique properties and potential applications in improving drug solubility, stability, bioavailability, and targeting.

Nanostructured lipid carriers (NLCs) are second-generation lipid nanoparticles that evolved from solid lipid nanoparticles (SLNs). They consist of a lipid matrix with a unique nanostructure, typically composed of a blend of solid lipids and liquid lipids or surfactants. This combination allows for better loading capacity and drug release characteristics compared to SLNs.

NLCs represent a significant advancement over their predecessors, Solid Lipid Nanoparticles (SLNs), by virtue of their unique nanostructure and composition. While SLNs consist of a solid lipid matrix, NLCs incorporate both solid lipids and liquid lipids or surfactants, resulting in a structured yet imperfect lipid matrix. This composition enables NLCs to achieve a higher drug loading capacity, improved stability, and controlled drug release kinetics, thereby addressing critical challenges in pharmaceutical formulation.

The distinctive nanostructure of NLCs, characterized by a disordered lipid matrix with imperfections, plays a pivotal role in their functionality. These imperfections, such as crystalline defects and interstitial spaces, facilitate the entrapment and controlled release of drugs, enhancing their bioavailability and therapeutic efficacy. Moreover, the flexibility in lipid composition allows for precise modulation of drug release profiles, making NLCs adaptable to a wide range of therapeutic applications.

The multifaceted advantages of NLCs extend across diverse applications in pharmaceutical and biomedical fields. From oral drug delivery to topical and transdermal administration, NLCs offer targeted and sustained release of therapeutics, thereby optimizing therapeutic outcomes while minimizing adverse effects. Furthermore, their biocompatibility and biodegradability position NLCs as promising candidates for imaging and diagnostic applications, underscoring their utility beyond traditional drug delivery roles.

Despite their considerable promise, challenges persist in the widespread adoption of NLCs, including scale-up production, stability concerns, and regulatory considerations. Addressing these challenges necessitates ongoing research efforts aimed at optimizing formulation parameters, elucidating mechanisms of action, and conducting rigorous preclinical and clinical studies to validate the safety and efficacy of NLC-based drug delivery systems.

Nanostructure and Composition of Nanostructured Lipid Carriers (NLC):

The nanostructure and composition of Nanostructured Lipid Carriers (NLCs) constitute fundamental aspects defining their unique properties and functionality in drug delivery. Unlike conventional lipid-based nanoparticles, NLCs possess a distinctive nanostructure characterized by a finely tuned combination of solid lipids and liquid lipids or surfactants. This composition imbues NLCs with exceptional versatility and efficacy in encapsulating therapeutic agents while overcoming inherent limitations of conventional drug delivery systems.

At the core of NLCs lies a lipid matrix, typically comprising a blend of lipids carefully selected to achieve optimal drug loading and release characteristics. Solid lipids form the backbone of this matrix, providing structural integrity and stability to the nanoparticle. These solid lipids encompass a diverse range of compounds, including long-chain fatty acids, glycerides, and waxes, each offering unique properties such as crystallinity, melting point, and compatibility with encapsulated drugs.

Incorporated within the solid lipid matrix are liquid lipids or surfactants, which play a crucial role in modulating the nanostructure of NLCs. These liquid lipids, which may include oils, phospholipids, or nonionic surfactants, introduce imperfections into the lipid matrix, thereby preventing complete

crystallization and promoting the formation of a nanostructured network. These imperfections, such as crystalline defects, disordered regions, and interstitial spaces, create reservoirs within the NLCs for the entrapment and controlled release of therapeutic payloads.

The presence of liquid lipids or surfactants in NLC formulations offers several advantages over conventional Solid Lipid Nanoparticles (SLNs). By disrupting the regular packing of solid lipids, these additives enhance the loading capacity of NLCs and mitigate issues related to drug expulsion during storage. Additionally, the incorporation of liquid lipids improves the flexibility and deformability of NLCs, facilitating their interactions with biological membranes and enhancing drug permeation across physiological barriers.

The precise composition and ratio of solid lipids to liquid lipids or surfactants are critical determinants of the nanostructure and performance of NLCs. Optimization of these parameters enables tailoring of NLC formulations to specific drug delivery requirements, including desired drug release kinetics, stability under physiological conditions, and compatibility with target tissues or cells. Furthermore, the selection of biocompatible and biodegradable lipid components ensures the safety and tolerability of NLC-based drug delivery systems for clinical applications.

Preparation Methods of Nanostructured Lipid Carriers (NLC):

The preparation methods of Nanostructured Lipid Carriers (NLCs) encompass a diverse array of techniques, each tailored to achieve specific formulation goals while ensuring reproducibility, scalability, and control over particle properties. These methods leverage principles of nanotechnology and colloidal science to create nanostructured lipid matrices capable of encapsulating therapeutic payloads with precision and efficiency.

1. **High-Pressure Homogenization**: High-pressure homogenization is one of the most widely employed techniques for preparing NLCs. This method involves subjecting a lipid mixture, comprising solid lipids and liquid lipids or surfactants, to intense mechanical forces generated by high-pressure homogenizers. The lipid mixture is passed through a narrow gap or nozzle, resulting in intense shearing forces that disrupt lipid aggregates and promote the formation of nano-sized particles. Control over processing parameters such as pressure, number of cycles, and lipid composition allows for precise modulation of particle size, distribution, and drug loading.



Figure 1: High-Pressure Homogenization

Merits:
- High-pressure homogenization allows for precise control over particle size and distribution, leading to uniform NLC formulations.
- This method is suitable for large-scale production and offers scalability.
- It facilitates high drug loading efficiency and encapsulation of hydrophobic and hydrophilic drugs.
- High-pressure homogenization can yield stable NLC formulations with prolonged shelf-life.

Demerits:
- High-energy input required during homogenization may lead to lipid degradation or drug instability.
- Equipment costs can be substantial, particularly for industrial-scale homogenizers.
- Variability in particle size and polydispersity may occur if process parameters are not optimized.

2. **Solvent Evaporation**: Solvent evaporation techniques involve dissolving lipids and drugs in a volatile organic solvent followed by solvent removal to induce nanoparticle formation. In the case of NLCs, a lipid mixture containing solid lipids and liquid lipids or surfactants is dissolved in an organic solvent, and the resulting solution is emulsified in an aqueous phase containing stabilizers. Subsequent evaporation of the organic solvent under controlled conditions leads to the formation of NLCs with a well-defined nanostructure. This method offers versatility in terms of lipid selection and allows for the incorporation of heat-sensitive drugs, albeit with potential challenges related to solvent removal and particle aggregation.

Merits:
- Solvent evaporation methods allow for the encapsulation of a wide range of drugs, including heat-sensitive compounds.
- Versatility in lipid selection enables customization of NLC formulations for specific drug delivery needs.
- This method offers control over particle size, morphology, and drug release kinetics.
- Solvent evaporation techniques can be adapted for both laboratory-scale and industrial-scale production.

Demerits:
- Residual solvent traces may pose safety concerns and require stringent purification steps.
- Solvent evaporation may result in low drug loading efficiency and loss of volatile compounds.
- Aggregation or fusion of nanoparticles may occur during solvent removal, leading to inconsistent particle size distribution.
- Complexity and time-consuming nature of the process may limit its applicability for large-scale production.

3. **Hot and Cold Homogenization**: Hot and cold homogenization techniques involve manipulating the temperature of lipid mixtures to induce phase transitions and nanostructure formation. In the hot homogenization method, the lipid mixture is heated above the melting point of solid lipids to achieve a homogeneous melt, which is subsequently cooled under high shear conditions to induce nanoparticle formation. Conversely, in the cold homogenization method, the lipid mixture is initially cooled to induce crystallization of solid lipids, followed by homogenization to disrupt lipid crystals and generate NLCs. These methods offer precise control over particle size and structure, making them suitable for sensitive drugs and bioactive compounds.

Merits:
- Hot and cold homogenization methods offer versatility in lipid selection and compatibility with sensitive drugs.
- These techniques allow for precise control over particle size, structure, and drug release kinetics.
- Low processing temperatures minimize the risk of lipid degradation and drug instability.
- Hot homogenization can facilitate rapid nanoparticle formation, while cold homogenization may enhance drug encapsulation efficiency.

Demerits:
- Hot homogenization may require additional steps for lipid melting and homogenization, prolonging processing time.
- Cold homogenization may result in lower drug loading efficiency compared to other methods.
- Optimization of temperature and homogenization parameters is crucial to avoid particle aggregation or crystal growth.

4. **Microemulsion Techniques**: Microemulsion techniques involve the spontaneous formation of thermodynamically stable emulsions comprising oil, water, surfactants, and co-surfactants. NLCs can be prepared using microemulsion templates by incorporating lipid components into the oil phase of the microemulsion system. Upon destabilization of the microemulsion, typically induced by dilution or temperature change, NLCs are formed as a result of lipid phase separation and nanostructure formation. Microemulsion-based methods offer advantages such as rapid nanoparticle formation, uniform particle size distribution, and potential for encapsulating hydrophobic and hydrophilic drugs.

Merits:
- Microemulsion techniques offer rapid and efficient nanoparticle formation under mild processing conditions.
- The versatility of microemulsions allows for encapsulation of hydrophobic and hydrophilic drugs.
- Uniform particle size distribution and high encapsulation efficiency can be achieved.
- Microemulsion-based methods are amenable to scale-up and industrial production.

Demerits:
- Formulation complexity may increase due to the requirement for multiple components in the microemulsion system.
- Surfactant toxicity or irritation may limit biomedical applications.
- Stability issues, such as phase separation or Ostwald ripening, may occur during storage.
- Optimization of microemulsion compositions and processing parameters is essential to ensure reproducibility and stability of NLC formulations.

Applications:

Nanostructured lipid carriers (NLCs) have garnered considerable interest in various biomedical and pharmaceutical fields due to their unique properties and versatile applications. Here are some key applications of NLCs:

1. **Drug Delivery**:
- Oral Drug Delivery: NLCs can improve the oral bioavailability of poorly water-soluble drugs by enhancing their solubility, stability, and absorption in the gastrointestinal tract.

- Topical and Transdermal Delivery: NLCs offer controlled release and enhanced penetration of drugs through the skin, making them suitable for dermatological and transdermal drug delivery applications.
- Parenteral Delivery: NLCs can be administered intravenously or via other parenteral routes to achieve targeted drug delivery, prolonged circulation time, and reduced systemic toxicity.

2. **Cancer Therapy**:
- Targeted Drug Delivery: NLCs can be functionalized with ligands or antibodies to selectively target cancer cells, improving the efficacy of chemotherapy while minimizing off-target effects.
- Combination Therapy: NLCs enable the co-delivery of multiple therapeutic agents, such as chemotherapeutic drugs and nucleic acid-based therapeutics, for synergistic anticancer effects.

3. **Ophthalmic Delivery**:
- NLCs can be formulated into eye drops or ointments for the treatment of ocular diseases, offering improved drug solubility, prolonged retention on the ocular surface, and enhanced corneal penetration.

4. **Imaging and Diagnostics**:
- Contrast Agent Delivery: NLCs loaded with imaging contrast agents, such as magnetic resonance imaging (MRI) or computed tomography (CT) contrast agents, enable enhanced visualization of tissues and organs for diagnostic purposes.
- Theranostics: NLCs can be engineered to combine diagnostic imaging capabilities with therapeutic functionalities, allowing for simultaneous imaging and targeted drug delivery.

5. **Nutraceuticals and Cosmeceuticals**:
- NLCs serve as effective carriers for the encapsulation and delivery of nutraceuticals, vitamins, antioxidants, and other bioactive compounds, enhancing their stability and bioavailability.
- Cosmeceutical formulations containing NLCs offer improved skin penetration and controlled release of active ingredients for enhanced skincare and cosmetic applications.

6. **Gene Delivery**:
- NLCs can be employed as non-viral vectors for the delivery of nucleic acid-based therapeutics, such as plasmid DNA, small interfering RNA (siRNA), or messenger RNA (mRNA), for gene therapy applications.
- The biocompatibility and ability to protect nucleic acids from degradation make NLCs promising candidates for gene delivery with reduced immunogenicity and off-target effects.

7. **Veterinary Medicine**:
- NLCs have applications in veterinary medicine for improving the delivery of drugs to animals, including livestock, pets, and wildlife, offering enhanced efficacy, safety, and convenience in medication administration.

Conclusion:

In conclusion, Nanostructured Lipid Carriers (NLCs) represent a versatile and promising platform for drug delivery and biomedical applications. With their unique nanostructure and composition, NLCs offer several advantages, including enhanced drug solubility, stability, bioavailability, and targeted delivery. These colloidal nanoparticles have found applications across various fields, including

pharmaceuticals, cancer therapy, ophthalmology, imaging, nutraceuticals, gene therapy, and veterinary medicine.

Acknowledgements:

Authors wish to thank “Channabasweshwar Pharmacy College (Degree), Latur” for providing technical assistance to work, and conduct PhD work. The authors acknowledge the financial assistance provided by “MAHAJYOTI, Nagpur”.

References:

1. Müller RH, Radtke M. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev. 2002;54(Suppl 1):S131-S155.
2. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(Suppl 1):S131-S155.
3. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3):165-196.
4. Radtke M, Müller RH. Nanostructured lipid carriers: the missing link between liposomes and solid lipid nanoparticles. Eur J Pharm Biopharm. 2001;53(3):255-262.
5. Wissing SA, Müller RH. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release. 2003;81(3):225-233.
6. Hu FQ, Jiang SP. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm. 2007;342(1-2):201-207.
7. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289-300.
8. Zhang H, Zhang J. Solid lipid nanoparticles with monodisperse and core-shell structure for drug delivery. Colloids Surf B Biointerfaces. 2008;65(2):255-259.
9. Zhang X, Zhang J. Effects of formulation factors on encapsulation efficiency and release behaviour in vitro of huperzine A-PLGA microspheres. Colloids Surf B Biointerfaces. 2008;61(1):75-79.
10. Hu FQ, Yuan H. Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm. 2008;355(1-2):293-300.
11. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257-1272.
12. Nasr M, Abdel-Hamid S. Optimization of a nanostructured lipid carrier formulation for the poorly water-soluble drug, quercetin using a full factorial design. Pharmazie. 2007;62(12):944-947.
13. Souto EB, Müller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Drug DelivTransl Res. 2008;6(6):427-443.
14. Salvi VR, Pawar P. Nanostructured lipid carriers (NLCs) - A review. Int J Pharm Sci Res. 2011;2(1):34-41.
15. Shete RT, Pawar AP. Formulation and evaluation of optimized nanostructured lipid carrier (NLC) for topical delivery of mometasonefuroate. Future J Pharm Sci. 2018;4(2):164-170.
16. Yang S, Zhu J, Lu Y. A review of nanoparticle formulation of poorly water-soluble drugs and the effect of Eudragit® EPO on release behavior. Asian J Pharm Sci. 2011;6(4):211-220.
17. Yuan Y, Huang Y. Preparation of solid lipid nanoparticles containing hydrophilic drug. Drug Deliv. 2012;19(6):364-369.
18. Zhang X, Zhang J, Ma Z. Solid lipid nanoparticles loading candesartan cilexetilenhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomedicine. 2010;6(6):943-950.

19. Kumar S, Singh A. Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig. 2019;9(4):163-173.
20. Ganesan P, Narayanasamy D. Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustainable Chem Pharm. 2019;14:100190.
21. Müller RH, Shegokar R. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev. 2008;60(4-5):729-746.
22. Mishra V, Bansal KK. Nanostructured lipid carriers: A review. NanosciNanotechnolLett. 2019;11(9):1296-1309.
23. Souto EB, Müller RH. Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci. 2008;30(3):157-165.
24. Parhi R, Suresh P. Preparation and characterization of nanostructured lipid carriers-a review. Acta Pharm Sin B. 2012;2(4):307-315.
25. Chauhan I, Yasir M. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery. Int J Pharm Drug Anal. 2013;1(1):19-34.
26. Mukherjee S, Ray S. Thymoquinone encapsulated nanostructured lipid carrier: challenges in oral cancer treatment. J Drug DelivSci Technol. 2019;51:641-651.
27. Zeb A, Qureshi OS. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. J Pharm Pharmacogn Res. 2018;6(4):225-238.
28. Hu FQ, Yuan H. Development of new colloidal carriers for transdermal drug delivery. Curr Drug Deliv. 2002;4(4):321-327.